Neurotech International Ltd (asx:NTI) Share Price

Company Profile

Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUS
T: +61 394983132
https://www.neurotechinternational.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
18

Recommended

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Brian Colello, CPA | 23 July 2026

A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.

Tyger Fitzpatrick | 23 July 2026

Where value remains in Australian banks.

Tyger Fitzpatrick | 23 July 2026

Index	Last price	Change	% Change
All Ordinaries	9,018.10	41.40	-0.46%
CAC 40	8,344.60	93.29	-1.11%
DAX 40	25,001.59	153.82	-0.61%
Dow JONES (US)	52,218.58	6.06	-0.01%
FTSE 100	10,700.50	16.47	-0.15%
HKSE	25,210.81	318.15	1.28%
NASDAQ	25,690.90	146.30	-0.57%
Nikkei 225	66,422.60	307.00	0.46%
NZX 50 Index	13,795.31	32.13	0.23%
S&P 500	7,498.96	10.24	-0.14%
S&P/ASX 200	8,839.00	38.60	-0.43%
SSE Composite Index	3,876.78	9.74	0.25%